Lung Cancer

Emrelis is a groundbreaking treatment for advanced non-small cell lung cancer, targeting high c-Met protein overexpression.

Biomarker testing transforms non-small cell lung cancer treatment, enhancing outcomes through targeted therapies and next-generation sequencing for better patient care.

Zoldonrasib, a novel oral KRAS G12D-selective inhibitor, demonstrated promising safety and early antitumor activity in patients with previously treated non–small cell lung cancer (NSCLC), offering a potential new targeted therapy for this underserved population.

Though new treatments offer hope, careful monitoring and understanding of risks remain essential for their success.

Nicolas Girard, MD, explains the benefits observed in the MARIPOSA clinical trial among patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated with amivantamab plus lazertinib.

The antibody-drug conjugate is currently undergoing evaluation in a phase 1 trial that enrolled patients with pancreatic cancer and squamous non-small cell lung cancer (NSCLC).

PD-L1 immune checkpoint inhibitors are now standard for early-stage non-metastatic non-small cell lung cancer (NSCLC), with neoadjuvant, adjuvant, and perioperative strategies improving survival and outcomes.

Megan May, PharmD, BCOP, FHOPA, FAPO, discusses lurbinectedin and tarlatamab and what ongoing research in the small cell lung cancer (SCLC) space entails.

After decades without improvements, an expert with Baptist Health described the small cell lung cancer (SCLC) space as “exciting” following multiple innovations in the past few years.

Tarlatamab was approved by the FDA in May 2024 for patients who progressed after platinum-based chemotherapy.

The Western diet was associated with increased risk of lung cancer.

Trastuzumab rezetecan is a novel antibody-drug conjugate.

Glecirasib is a potent oral inhibitor of KRASG12C.

The administration of immunotherapy in adjuvant, neoadjuvant, and perioperative settings offers distinct benefits and challenges in resectable cancers, with recent clinical trials highlighting its potential to improve long-term outcomes and the need for further research into biomarkers and combination strategies.

Priority review status will allow for expedited development of zongertinib, putting it on the path toward approval as the first in a new class of drugs for mutated NSCLC.

Second-line and later treatment options for small cell lung cancer are limited.

DLL3 is an emerging therapeutic target in small cell lung cancer and other neuroendocrine carcinomas, with 1 FDA-approved therapy and several others under investigation.

The cancer cells developed their own electrical network similar to neural behavior seen in the brain.

Up to 61% of all non-small cell lung cancer (NSCLC) cases harbor EGFR mutations.

Edward Kim, MD, MBA, discusses critical points of patient leakage in precision medicine, emphasizing the role of multidisciplinary teams in streamlining care, managing medications, and improving patient outcomes.

Edward Kim, MD, MBA, highlights the challenges of patient disengagement, data fragmentation, and provider education in precision medicine, emphasizing the need for personalized approaches to enhance patient outcomes, particularly in oncology.

The study results build on the “obesity paradox,” which suggests that patients with cancer and obesity have better outcomes.

As lung cancer cases rise, there is a significant need for therapeutic options that meet the challenges and needs of individual patients.

Preliminary phase 1 trial results demonstrate that patients with small cell lung cancer generated early clinical activity after being administered ZL-1310.

The FDA proposes to cap the nicotine level at 0.7 mg per gram of tobacco in cigarettes and certain other combusted tobacco products.

Radon is a tasteless, odorless radioactive gas associated with DNA damage and high genomic tumor instability.

Wildfire smoke carries toxic compounds that can trigger respiratory inflammation and cause cellular damage.

According to the investigators, BBO-8520 represents a first-in-class approach to treating patients with previously treated KRASG12C-mutated metastatic non-small cell lung cancer (NSCLC).

Datopotamab deruxtecan was also granted breakthrough therapy designation in December 2024.

In a phase 2 trial (NCT05400226), abenacianine helps surgeons visualize tumors in lung during surgery and is safe and well-tolerated in patients.